BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22771484)

  • 1. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.
    Flowers CR; Fedewa SA; Chen AY; Nastoupil LJ; Lipscomb J; Brawley OW; Ward EM
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1520-30. PubMed ID: 22771484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study.
    Lee SF; Evens AM; Ng AK; Luque-Fernandez MA
    Sci Rep; 2021 Sep; 11(1):17950. PubMed ID: 34504223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insurance status is related to diffuse large B-cell lymphoma survival.
    Han X; Jemal A; Flowers CR; Sineshaw H; Nastoupil LJ; Ward E
    Cancer; 2014 Apr; 120(8):1220-7. PubMed ID: 24474436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
    Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
    Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
    Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
    Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
    Olszewski AJ; Winer ES; Castillo JJ
    Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
    Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
    Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults.
    Guadamuz JS; Ozenberger K; Qato DM; Ko NY; Saffore CD; Adimadhyam S; Cha AS; Moran KM; Sweiss K; Patel PR; Chiu BC; Calip GS
    Medicine (Baltimore); 2019 Nov; 98(46):e17960. PubMed ID: 31725657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.
    Chiappella A; Santambrogio E; Castellino A; Nicolosi M; Vitolo U
    Expert Rev Hematol; 2017 Aug; 10(8):697-705. PubMed ID: 28665232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.
    Battella S; Cox MC; La Scaleia R; Di Napoli A; Di Landro F; Porzia A; Franchitti L; Mainiero F; Ruco L; Monarca B; Santoni A; Palmieri G
    Cancer Immunol Immunother; 2017 Oct; 66(10):1295-1306. PubMed ID: 28555258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
    Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
    Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
    Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Beltran BE; Quiñones P; Morales D; Malaga JM; Chavez JC; Sotomayor EM; Castillo JJ
    Hematol Oncol; 2018 Feb; 36(1):93-97. PubMed ID: 28639256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
    Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study.
    Di M; Keeney T; Belanger E; Huntington SF; Olszewski AJ; Panagiotou OA
    J Am Geriatr Soc; 2023 Jul; 71(7):2239-2249. PubMed ID: 36882865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
    Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
    Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
    Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
    Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).
    Griffiths R; Gleeson M; Knopf K; Danese M
    BMC Cancer; 2010 Nov; 10():625. PubMed ID: 21073707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.